Leaning Objectives
Upon completion of this activity, you should be able to:
- Evaluate the epidemiology, risk factors, comorbidities, and community aspects associated with HF to determine best practices for care.
- Distinguish pathophysiologic characteristics of current classifications of phenotypes when diagnosing HF to analyze best HF risk stratification, prevention, and management strategies.
Faculty
Alison Bailey, MD, FACC (Chair)
Centennial Heart at Parkridge
Consultant Fees/Honoraria: BMS, Medtronic, OptumRx
Melvin Echols, MD, MSCR, FACC (Chair)
Morehouse School of Medicine
Consultant Fees/Honoraria: Abbott Laboratories, Bayer Healthcare Pharmaceuticals, National Academy for Continuing Education, Novartis Corporation
Michelle Maya Kittleson, MD, PhD, FACC
Smidt Heart Institute at Cedar-Sinai
Target Audience
The primary target audience for this education are members of the HF Care Team, including physicians, advanced practice providers (APPs), PharmDs, and other HCPs.
Important Dates
Date of Release: January 23, 2026
Term of Approval/Date of Expiration: January 22, 2027
Acknowledgement
This activity is supported by an unrestricted educational grant from Bayer AG.